

REMARKS/ARGUMENTS

Claims 7-10 and 30-47 are active with Claims 30-33 and 38-43 being withdrawn based on the restriction imposed by the Office.

Chlamydia bacteria, which are gram negative bacteria, are human pathogens causing a number of diseases (see page 1 of the specification). Part of the pathogenesis of Chlamydia involves the expression and secretion of a number of proteins (see pages 2-4 of the specification). Generally, protein secretion in gram negative bacteria, involves at least four different pathways (page 5, 1st full paragraph of the specification). As discussed in the paragraph bridging pages 5-6 of the specification, since there are no genetic tools to manipulate and study Chlamydia gene expression and protein secretion, another way to analyze Chlamydia gene expression and pathogenesis.

In view of this background, “the inventors have shown that several chlamydial proteins, including members of the Inc family and proteins selected for a hydrophobic profile similar to that of Inc proteins, are secreted by the type II secretion machinery of *S. flexneri*.” (*S. flexneri* is a Shigella specie). Thus, to better understand the pathogenesis of the Chlamydia bacteria and to develop ways to better diagnose infection and devise treatments, the present inventors have discovered that Chlamydia proteins can be expressed and detected in gram negative bacterial cell resulting in the claimed invention relating to a method for identifying a secreted *Chlamydia* polypeptide by causing expression of a polypeptide of interest in a Gram-negative strain containing a type III secretion pathway and subsequently determining whether the protein is secreted.

In the Office Action the rejection of Claims 7-10, 34-37 and 44-47 has been maintained in view of the previously cited Graffais, Demers and Kalman documents. In addition, a new rejection centering on the disclosure in U.S. Patent No. 6,822,071 (Stephens, et al) combined Demers is also asserted.

To the maintained rejection, Applicants request reconsideration in light of the following discussion.

The claimed invention is to an entirely different method of identifying secreted Chlamydia proteins compared to what is described or suggested by the combination of cited art. Specifically, Demers describes screening for agent/compounds that **change the expression** of type III secretory proteins and/or which **block secretion** through this pathway. Specifically, pages 1, lines 8-9, page 2, lines 14-16 and page 3, lines 1-2 of Demers:

The invention also provides methods of identifying molecules that are able to activate or inhibit secretion in wild-type strains of gram-negative bacteria. Page 3, lines 1-2 of Demers

Graffais describes a number of Chlamydia proteins some of which are characterized as Type II secreted proteins (see, e.g., col. 22, lines 62-67). The Office cites column 40 of Graffais for a teaching of expressing proteins and detecting them using any known technique (see Advisory Action at page 3). However, Graffais' teachings are not focused on this but rather disclose the genes and then go on to describe that the genes and their corresponding proteins could be used for almost any imaginable use of such molecules, e.g., hybridization, eliciting an immune response, identifying compounds which block pathogenesis and others (see col. 43, lines 1-13; col. 50, lines 4-16), col. 59, line 57 to col. 60, line 16; col. 60, lines 46-56; col. 61, lines 21-33 and col. 63, lines 1-8).

Kalman is cited merely for the proposition that certain Chlamydia genes were known (see page 4 of the final Office Action and page 3 of the Advisory Action) but does not add anything relating to the method as claimed.

The Office's rationale for maintaining the rejection as stated on page 4 of the Official Action lacks merit for two reasons.

First, one would not have used Demers secretion system as alleged by the Office because doing so would be contrary to what is taught. Specifically, Demers entire disclosure is directed to looking for agents that block secretion or change expression patterns NOT for determining whether a certain Chlamydia protein is one that can be secreted through the type III pathway.

Second, the cited art provides no reason to believe that the expression of Chlamydia proteins would, in fact, work in other gram negative strains such as Shigella. No evidence as to why the Office concludes that genes from such different organisms would be expressed nor would be properly secreted by the Type III machinery of that cell. The Office simply makes a conclusion without supporting facts. The Office should take note that as a prelude to the Inventors description that they have discovered that certain Chlamydia proteins could be expressed and secreted in Shigella, the Inventors state that another prior art publication in *Molecular Microbiology* describes expression of other proteins in Shigella, there are phylogenic differences between Chlamydia from other organisms (see page 7 of the specification) and therefore it is implied that no *a priori* conclusion could be drawn as to the success of expression of Chlamydia proteins in other bacterial cells, such as Shigella.

Moreover, heterologous secretion of a secreted Chlamydia polypeptide can be obtained only if the signal of the Chlamydia polypeptide is identical to the signal of the bacteria in which the secretion is tested. This was not obvious for Shigella first because the signal is still unknown and second because of the phylogenic distance of Chlamydia with the other organisms (see paragraph 10 of the specification). One could have thought that the signals had become different during evolution. This is particularly strengthen by the fact that it is known that the proteins which make the Chlamydia secretion machinery are not well conserved compared to the protein which make the secretion machinery of bacteria as Yersinia, Salmonella, Pseudomonas etc. which could also have been used as models.

In addition, many secreted proteins need to be expressed together with a chaperone protein. Examples in the literature for the necessity of coexpressing a chaperone protein to get secretion in *Salmonella* are listed below (Abstracts are attached for reference):

Parsot et al Curr Opin Microbiol. 2003 Feb;6(1):7-14

Tuckerdagger and Galan, J Bacteriol. 2000 Apr;182(8):2262-8

For the presence of functional chaperone proteins in *Chlamydia*, see below (Abstracts attached):

Fields et al J Bacteriol. 2005 Sep;187(18):6466-78

Slepenkin et al J Bacteriol. 2005 Jan;187(2):473-9

And again, Demers does not describe the use of their system as a screening method for discovering new secreted proteins, but only as a screening method for finding inhibitors/activators of secretion.

In view of the above, the combination of Demers, Graffais and Kalman fail to describe a method for identifying a secreted *Chlamydia* polypeptide including the steps as set forth in independent Claims 7 and 8. As the combination of cited publications fail to describe or suggest each and every limitation of the claimed invention, withdrawal of the rejection under 35 U.S.C. § 103(a) is requested.

To the newly raised rejection, it should be recognized that the Stephens patent describes the identification of *chlamydia* polypeptides and also that these polypeptides can be expressed from cells transformed with the corresponding nucleic acids using conventional cell lines such as *E. coli* (see columns 15-16).

The Examiner acknowledges that the Stephens patent does not describe the expression of *chlamydia* polypeptides in gram-negative bacterial strains containing a type III secretion

pathway but for this the Examiner relies again on the Demers disclosure. On this basis, the Examiner alleges that one would have expressed the proteins in Stephens using the bacteria strains described in Demers. (see discussion on pages 5-6 of the Official Action).

Applicants disagree.

Neither of Stephens nor Demers describes a method for identifying secreted proteins but rather the general methodology for expressing proteins (which is even acknowledged by Stephens in column 15). It must be understood that expression of a protein and secretion of the same are not necessarily the same thing, e.g., a protein can be expressed without also being secreted.

Again, Demers describes screening for agent/compounds that **change the expression** of type III secretory proteins and/or which **block secretion** through this pathway (see pages 1, lines 8-9, page 2, lines 14-16 and page 3, lines 1-2 of Demers). Therefore, Demers combined with Stephens simply fails to teach and/or suggest the claimed invention.

Moreover, heterologous secretion of a secreted Chlamydia polypeptide can be obtained only if the signal of the Chlamydia polypeptide is identical to the signal of the bacteria in which the secretion is tested. This was not obvious for Shigella first because the signal is still unknown and second because of the phylogenic distance of Chlamydia with the other organisms (see paragraph 10 of the specification). One could have thought that the signals had become different during evolution. This is particularly strengthened by the fact that it is known that the proteins which make the Chlamydia secretion machinery are not well conserved compared to the protein which make the secretion machinery of bacteria as Yersinia, Salmonella, Pseudomonas etc. which could also have been used as models.

Application No. 10/014,670

Reply to Office Action of May 5, 2006

And again, Demers does not describe the use of their system as a screening method for discovering new secreted proteins, but only as a screening method for finding inhibitors/activators of secretion.

Accordingly, withdrawal of the rejection based on Stephens and Demers is requested.

A Notice of Allowance is also requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon



Daniel J. Pereira, Ph.D.
Registration No. 45,518

Customer Number

22850

Tel: (703) 413-3000

Fax: (703) 413 -2220

(OSMMN 06/04)